We are pleased to share that today we have initiated patient dosing in a Phase 1/2 study of AT-1965 a CMTR2 inhibitor in patients with solid tumors. A huge thank you to the many people who dedicated countless hours to help bring AT-1965 into clinic trials.
Alyssum Therapeutics’ Post
More Relevant Posts
-
Learn about NEXUS-01, our Phase 1 trial of an investigational #Nectin4 targeted antibody-drug conjugate in patients with advanced or metastatic #UrothelialCarcinoma or other solid tumors. Find detailed trial and enrollment information here: https://e.lilly/3VR2ns8 #CancerResearch #ClinicalTrials #ADCs #BladderCancer
-
-
Excited to share we’ve dosed our first patient in the Phase 1/1b clinical trial of QTX3046, an oral, dual (OFF/ON)-state KRASG12D-selective inhibitor and initiated patient dosing in the combination portion of the ongoing Phase 1 trial assessing QTX3034, a G12D-preferring multi-#KRAS inhibitor. Both are enrolling patients with KRASG12D-mutated advanced solid tumors. Learn more: https://bit.ly/4ciYUZ0
-
-
With the advancement of two clinical trials treating KRAS G12D mutated cancers and the initiation of GLP toxicology studies for QTX3544, a G12V-preferring multi-#KRAS inhibitor, we aim to address the significant unmet need for patients with KRAS-mutated cancer beyond G12C.
Excited to share we’ve dosed our first patient in the Phase 1/1b clinical trial of QTX3046, an oral, dual (OFF/ON)-state KRASG12D-selective inhibitor and initiated patient dosing in the combination portion of the ongoing Phase 1 trial assessing QTX3034, a G12D-preferring multi-#KRAS inhibitor. Both are enrolling patients with KRASG12D-mutated advanced solid tumors. Learn more: https://bit.ly/4ciYUZ0
-
-
We’re assessing a #PanKRAS inhibitor as a monotherapy and in combination in patients with certain #KRAS mutant solid tumors. Learn more about the Phase 1a/1b trial: https://e.lilly/4fnMGje
-
-
#Halozyme and #BristolMyersSquibb have achieved a significant milestone with the FDA approval of Opdivo® with Enhanze® for subcutaneous use, marking progress in adult solid tumor treatment. Explore their innovative approach. Click to learn more! 👉 https://bit.ly/3WnAXdt
-
-
An FGFR1/2/3 inhibitor combined with chemotherapy or immunotherapy was evaluated in solid tumors in an open-label, Phase 1/2 study. Learn more about our findings in patients with FGFR alterations. https://bit.ly/3yt2D7V
New Publication for Patients with Advanced Malignancies
-
Please read our paper just published in JITC. Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden. https://lnkd.in/eXwDBGZc https://lnkd.in/ecqjqda3
-
🚨 NEWS 🚨 First patient dosed in the phase I/II multicenter, open-label DAHLIA trial of REC-1245, a selective RBM39 degrader, for the treatment of patients with #lymphoma and biomarker-enriched solid tumors. Read more here: https://loom.ly/jaUQkfo #lymsm #MedNews
-
-
📢 We've achieved significant progress in a triple-combination therapy (afuresertib+Sintilimab+nab-paclitaxel) in patients with specific solid tumors who were resistant to anti-PD-1/PD-L1 therapy. The data will be presented at IGCS! Find More 👉https://lnkd.in/g7yzPyEq #IGCS #AKTInhibitor #Laekna #CervicalCancer #EndometrialCancer
-
-
"Specialist Medical Oncology in Burjeel medical city Abu Dhabi, Doh& DHA &MOH Licence 🇦🇪🇸🇾, ESMO Member, and Collaborator Extraordinaire - Let's Connect on Telegram and DM for Inspiring Partnerships!"
⏰NOW OUT‼️ #ASCO24🔥Educational Book ✅New Tx Options for Oncogene-Addicted NSCLC Focusing on EGFR-Mutant Tumors. ✅NSCLC Metastatic Without Oncogenic Alterations. links are in the comments below
-
Techno-Commercial Leader I Lead Generation I Project Management I Operational Excellence
7moCongratulations